Literature DB >> 25006949

Spontaneous resolution of nontraumatic chronic subdural hematoma associated with anti-aggregation therapy.

Shaofeng Yang1, Xiaohua Zhang, Yichao Jin.   

Abstract

Spontaneous resolution of chronic subdural hematoma (CSDH) is rare, especially for the nontraumatic cases. Here, we present 1 case of a 70-year-old female patient with spontaneous resolution of CSDH. She was chronically anticoagulated after percutaneous coronary intervention. Moreover, she denied previous mild head trauma and bleeding episodes. For personal reasons, she declined surgery. Treatment just included mannitol, which was used to alleviate the symptoms. Intermittent computed tomography showed gradually resolution of CSDH. Spontaneous resolution of nontraumatic CSDH is rare, with different mechanisms and computed tomography characteristics compared with that of traumatic CSDH. Dimerized plasmin fragment D in venous blood may be more sensitive in the judgment of types of CSDH.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25006949     DOI: 10.1097/SCS.0000000000000814

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  3 in total

1.  Spontaneous Resolution of Non Traumatic Chronic Subdural Haematoma Despite Continued Antiplatelet Therapy: A Case Report.

Authors:  Ajeet Ramamani Tiwari; Shradha Maheshwari; Srikant Balasubramaniam; Tyagi Devendra; Hemantkumar Savant
Journal:  J Clin Diagn Res       Date:  2015-06-01

2.  Spontaneous Disappearance of a Large Chronic Subdural Hematoma: A Pleasant Surprise.

Authors:  Hanish Bansal; Anuj Mahajan; Apinderpreet Singh; Ashwani Chaudhary
Journal:  Indian J Surg       Date:  2015-08-27       Impact factor: 0.656

3.  Tranexamic acid to prevent operation in chronic subdural haematoma (TORCH): study protocol for a randomised placebo-controlled clinical trial.

Authors:  S Immenga; R Lodewijkx; Y B W E M Roos; S Middeldorp; C B L M Majoie; H C Willems; W P Vandertop; D Verbaan
Journal:  Trials       Date:  2022-01-18       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.